Providing options.
Delivering hope.

We are a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

Our third-generation cellular analysis platform unravels complex oncogenic activity molecular tests can’t detect.

See our approach

Our discoveries create new potential applications for targeted therapies.

View our pipeline

Our comparative analyses of different drugs use live patient tumor cells, revealing opportunities to develop first-in-class drugs.

Learn about Gedatolisib

News

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

See all news